Clinical Trial

Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

Study acronym: RAINBO-RED
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-26.
Trial Details
NCT Number NCT06712472
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: AstraZeneca
Conditions Endometrial Cancer, p53abn
Enrollment 554 participants
Start Date 2024-06-26
Primary Completion 2030-06 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20